# Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

> **NCT01397201** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 30 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo
- **DRUG:** BI 54903
- **DRUG:** Fluticasone propionate

## Key facts

- **NCT ID:** NCT01397201
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07-01
- **Primary completion:** 2011-12-23
- **Final completion:** 2011-12-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01397201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01397201, "Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01397201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*